BBTV

About Us

all episodes

2010 End-of-the-Year Review, with Dennis Purcell

Dennis Purcell 90x90
  1. The Battle for Genzyme, The Future of Orphan Diseases
  2. Uncertainty & the FDA. Are Investors Being Driven Away from the Biotech Industry?
  3. How Obama-care is Affecting the Mindset of Investors. Most Positive and Negative Events for 2010.
  4. What is Driving Emerging Markets? What Does China Need from Us?
  5. The pressure for 2-4 Year Exits. Predictions for 2011.

Genzyme / Sanofi : Why The Price Isn’t Quite Right

Biotech In the Money with Marina Bozilenko
  1. Genzyme / Sanofi : $75-80 per share, The Big Win-Win
  2. Biosimilars, the Abbreviated BLA, and TEVA’s Response Letter
  3. Hepatitis C News to be Expected in November (AASLD) – VRTX, MRK, BMY, GILD, JNJ
  4. Novartis’ Multiple Sclerosis Pill (Gilenya) Joepardizing the Biogen Idec Franchise?
  5. State of the Markets: “Healthiest Time for Mid-Caps in 10 years.”

Understanding the FDA – Biotech In the Money

Biotech In the Money with Marina Bozilenko
  1. Why the Paradigm Shift at the FDA, over the Past 5 Years?
  2. Is Anything Binding With the FDA Anymore, or Are Companies Just Not Listening?
  3. Chronic Disease vs. Critical Needs: the FDA Fast Track, and Recourses for Companies
  4. Biosimilars are Without a Champion at the FDA
  5. FDA Very Actively Enforcing Compliance Regulation
  6. If You Had Unlimited Powers, How Would You Reform the FDA?
  7. Combination Therapy in the Eyes of the FDA. Can We Let FDA Off the Hook? The System Return to a More Rational Process

Hepatitis C, Neurology, Healthcare Reform, Genetic Testing – Biotech in the Money

Biotech In the Money with Marina Bozilenko
  1. Meeting Update: Hepatitis C – 2010 EASL
  2. Meeting Update: Neurology – 2010 AAN
  3. Obama’s Healthcare Reform, Good for Pharma, Biotech, and Generics?
  4. Implications of the MYGN Suit, the Future of Genetic Testing
  5. Status of the Financial Markets, IPOs and FOs in the YTD

IPO Review, OSIP, Medivation, Xenoport, Genzyme – Biotech in the Money

Biotech In the Money with Marina Bozilenko
  1. The OSIP / Astellas Saga
  2. The 2010 Biotech IPO Review, 1st Quarter
  3. Medivation’s Phase 3 is a Total Bust. Will Dimebon get a Second Life?
  4. Xenoport’s Phase 3, Also a Bust. An Eleventh-hour FDA Decision?
  5. Good News of the Month : Acorda and Viropharma, Stories with Upside
  6. Big Pharma’s Cancer Setbacks, Arrr You Hungry for More Biotech?
  7. Shareholder Activism : What Carl Icahn Can and Cannot Do with Genzyme
  8. Next Month in Biotech, Events to Look Out For

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs

  • About the Show


    A financial perspective on hot industry topics, the state of the markets, and the inner-workings of the biotech industry.

    Hosted by Marina Bozilenko, Head of Biotechnology & Pharma, William Blair & Company.

  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved